The trajectory of companies tied to Sildenafil's history presents a complex investment landscape. While the initial surge generated substantial returns , generic copies have significantly diminished market share . Investing in associated pharmaceutical companies now requires a careful assessment of patent safeguards, evolving patient changes, and t